Landmark Series A round positions Australian biotech at the forefront of neurodegenerative disease innovation.
Landmark Series A round positions Australian biotech at the forefront of neurodegenerative disease innovation.
The CGM giant and smart ring innovator join forces to integrate biosensor data and reshape personal health tracking.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
Novo Nordisk’s oral obesity drug shows superior efficacy over Eli Lilly’s candidate, reshaping the competitive landscape in metabolic …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
Despite a muted IPO market and cautious M&A activity, biotech in 2024 proved that innovation never sleeps—especially when …
Clinical research in 2024 is progressing rapidly, driven by pioneering studies, technological innovation, and evolving regulatory frameworks that …
Already a subscriber? Log in